Patents Examined by Kimberly Ballard
  • Detection of aggregated proteins associated with neurodegenerative disease using a photooxidation-induced amplification immunoassay
    Patent number: 11320442
    Abstract: Disclosed is a method for body fluid-based neurodegenerative disease diagnosis through high-sensitive immunoassay of aggregated proteins by photooxidation-induced amplification. The method according to the present disclosure provides an effect of quantitatively analyzing aggregated proteins in the form of oligomers or monomers which are present in trace amounts in a body fluid and measures normal or abnormal protein aggregation by detecting the aggregated proteins in the form of oligomers or monomers with high sensitivity by reaction of antibody-conjugated enzymes selectively bound to the aggregated proteins with substrates and photooxidation-induced amplification, thereby allowing accurate diagnosis of a neurodegenerative disease.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: May 3, 2022
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Ji Yoon Kang, Min Cheol Park, Youhee Heo
  • Antibodies that bind to pathological Tau species and uses thereof
    Patent number: 11319365
    Abstract: The present disclosure relates to antibodies that bind selectively to pathological Tau, including compositions and methods relating to such antibodies, such as for treating tauopathies, neurodegenerative diseases associated with pathological aggregation of Tau.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: May 3, 2022
    Assignee: APRINOIA THERAPEUTICS LIMITED
    Inventors: Ming-Kuei Jang, Chin-Yin Tai
  • Methods of maintaining, expanding, and differentiating neuronal subtype specific progenitors
    Patent number: 11319527
    Abstract: Methods for expanding proliferating populations of neuronal subtype-specific progenitors and creating substantially pure populations of motor neurons are provided herein. In particular, the present invention provides methods for maintaining the unique gene profile and differentiation potential of neuronal subtype-specific progenitors, such as motor neuron progenitors and hindbrain serotonergic neural progenitors.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: May 3, 2022
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Su-Chun Zhang, Zhongwei Du
  • Methods for treatment or prevention of a neurological immunity disorder
    Patent number: 11312775
    Abstract: Methods of treating, preventing, inhibiting, delaying the onset of, or ameliorating a neurological immunity disorder can include administering an effective amount of a compound comprising an antibody or antigen binding fragment of an antibody to a subject in need of treatment, prevention, inhibition, delay of onset, or amelioration of a neurological immunity disorder. The antibody or the antigen binding fragment of an antibody binds specifically to CD49a.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: April 26, 2022
    Assignee: University of Virginia Patent Foundation
    Inventors: Jonathan Kipnis, Antoine Louveau
  • Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
    Patent number: 11312763
    Abstract: The invention is directed to a short term induction treatment with anti-N3pGlu A? antibodies of a disease characterized by deposition of A? in the brain, that include Alzheimer's disease (AD), Down's syndrome, and cerebral amyloid angiopathy (CAA). In certain embodiments, patients are administered an induction dose of 10 to 60 mg/kg of an anti-N3pGlu A? antibody for a period of 6 months or less.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: April 26, 2022
    Assignee: Eli Lilly and Company
    Inventors: Ronald Bradley Demattos, Michael Carl Irizarry
  • Assay for the detection of alpha-synuclein seeding activity associated with synucleinopathies
    Patent number: 11313867
    Abstract: Methods are disclosed for determining whether a subject has a synucleinopathy. Methods are also disclosed for detecting misfolded alpha synuclein (?Syn) in a biological sample or fraction thereof. These methods include the use of an ?Syn seeding assay.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: April 26, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Byron Winslow Caughey, Bradley Richard Groveman, Christina Doriana Groveman, Lynne DePuma Raymond, Andrew Gregory Hughson
  • DARPin reagents that distinguish Alzheimer's disease and Parkinson's disease samples
    Patent number: 11300576
    Abstract: Disclosed are diagnostics for neurodegenerative diseases, and in particular to design ankyrin repeat protein (DARPins) reagents that distinguish Alzheimer's disease (AD) from Parkinson's disease (PD). Methods of diagnosing, monitoring treatment efficacy and developing treatments for neurodegenerative diseases, such as AD and PD are disclosed based upon the use of the AD or PD specific DARPins.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: April 12, 2022
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Michael Sierks, Stephanie Williams
  • Mutant huntingtin-mediated protein dysfunction
    Patent number: 11298409
    Abstract: The present invention relates to methods of inhibiting neurodegeneration in a subject suffering from or genetically at risk and/or destined to develop Huntington's Disease comprising increasing, in neurons of the subject, the activity of the TIM23 mitochondrial protein import complex.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: April 12, 2022
    Assignees: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, WASHINGTON UNIVERSITY
    Inventors: Robert Friedlander, Hiroko Yano
  • Antibodies to amyloid beta
    Patent number: 11286297
    Abstract: Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: March 29, 2022
    Assignee: MEDIMMUNE LIMITED
    Inventors: Maria Groves, Suzanne Gustavsson, Kina Höglund, Chris Lloyd, Adrian Nickson, Camilla Niva, Sylvia Simon, David Lowne, Fraser Welsh, Per-Ola Freskgärd
  • Assembly of functionally integrated human forebrain spheroids and methods of use thereof
    Patent number: 11279914
    Abstract: Human pluripotent stem cells are differentiated in vitro into forebrain subdomain structures, which are then fused to generate an integrated system for use in analysis, screening programs, and the like.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: March 22, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jimena Andersen, Fikri Birey, Sergiu P. Pasca
  • Amyloid-beta-binding peptides and the use thereof for the treatment and diagnosis of Alzheimer's disease
    Patent number: 11274125
    Abstract: The invention relates to amyloid beta-binding peptides and the use thereof for the treatment and the diagnosis of Alzheimer's disease.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: March 15, 2022
    Assignee: PRIAVOID GMBH
    Inventor: Dieter Willbold
  • Anti-transthyretin antibodies
    Patent number: 11267878
    Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: March 8, 2022
    Assignees: Neotope Neuroscience Limited, University Health Network
    Inventors: Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
  • Diagnosis, prevention, and/or treatment of autoimmune diseases
    Patent number: 11266717
    Abstract: Compositions, methods, and kits are for the diagnosis, prevention and/or treatment of autoimmune diseases by detecting, targeting, and/or eliminating epitope-specific autoimmune cells. The compositions include a conjugate of an epitope and an agent that allows for detecting, targeting, and/or eliminating epitope-specific autoimmune cells.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: March 8, 2022
    Assignee: IMMUNOWORK, LLC
    Inventor: Quansheng Zhu
  • Biomarkers of autism spectrum disorder
    Patent number: 11268966
    Abstract: Methods for identifying metabolic signatures in blood plasma which are unique to autism are described herein. Samples are analyzed using multiple chromatographic-mass spectrometry-based techniques to orthogonally measure a broad range of small molecular weight metabolites differentially produced in autistic patient samples versus non-autistic control samples. These individual metabolites or a panel of such metabolites serve as metabolic signatures of autism. Such metabolic signatures are used in diagnostic methods to accurately identify individuals with autism spectrum disorder (ASD).
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: March 8, 2022
    Assignee: Stemina Biomarker Discovery, Inc.
    Inventors: Paul West, Robert E. Burrier, Laura Egnash, Alan Smith, Preeti Bais
  • Multiplex biomarker for use in evaluation of state of accumulation of amyloid B in brain, and analysis method for said evaluation
    Patent number: 11268965
    Abstract: Provided are a biomarker for evaluating a cerebral A? accumulation state using amyloid precursor protein (APP)-derived A? and A?-like peptides in a living body-derived sample as an index, and a method for analysis thereof. A marker for determining a cerebral A? accumulation state, the marker comprising a combination of at least two ratios selected from the group consisting of: a ratio of A?1-39 (SEQ ID NO.: 1) level to A?1-42 (SEQ ID NO.: 3) level: A?1-39/A?1-42; a ratio of A?1-40 (SEQ ID NO.: 2) level to A?1-42 (SEQ ID NO.: 3) level: A?1-40/A?1-42; and a ratio of APP669-711 (SEQ ID NO.: 4) level to A?1-42 (SEQ ID NO.: 3) level: APP669-711/A?1-42, in a living body-derived sample.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: March 8, 2022
    Assignees: Shimadzu Corporation, National Center for Geriatrics and Gerontology
    Inventors: Naoki Kaneko, Akinori Nakamura
  • Compositions and methods for treatment of GCASE related disease states
    Patent number: 11260106
    Abstract: Disclosed are compositions and methods of treating a neurodegenerative disease in an individual. The methods disclose administration of an Integrin ?4?1, Very Late Antigen-4 positive neural precursor cell (“VLA4+ NPC”) transfected with a lentivirus overexpressing wild type GCase to an individual having a neurodegenerative disorder. The neurodegenerative disease may include lipid storage diseases, for example Gaucher disease, Parkinson's disease (PD), Dementia with Lewy bodies.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: March 1, 2022
    Assignee: Children's Hospital Medical Center
    Inventor: Ying Sun
  • Anti-CD33 antibodies and methods of use thereof
    Patent number: 11254743
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: February 22, 2022
    Assignee: ALECTOR LLC
    Inventors: Patricia Culp, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Nels P. Nielson, Robert Pejchal
  • Multispecific binding molecules having specificity to dystroglycan and laminin-2
    Patent number: 11254737
    Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: February 22, 2022
    Assignee: SANOFI
    Inventors: Christian Beil, William H. Brondyk, Yangde Chen, Seng H. Cheng, Timothy D. Connors, Catherine Devaud, Dietmar Hoffmann, Christian Lange, Maureen Magnay, Tristan Magnay, Catherine Prades, Ercole Rao, Leila Sevigny, Ronnie Wei, Hongmei Zhao, Yunxiang Zhu
  • Immunoassay for detecting tumor pyruvate kinase M2
    Patent number: 11255856
    Abstract: An immunoassay kit including a monoclonal antibody coupled to a labeling agent (labeled mAb) for detecting tumor pyruvate kinase M2 (tM2-PK) in a biological sample. The monoclonal antibody includes a heavy chain variable region (HCVR) including heavy chain complementarity-determining regions (CDRs) (SEQ ID NOs: 3, 4, and 5) and a light chain variable region (LCVR) including light CDRs (SEQ ID NOs: 7, 8, and 9).
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: February 22, 2022
    Assignee: TARBIAT MODARES UNIVERSITY
    Inventor: Mahboubeh Razzaqi
  • Agonist of spexin-based galanin type 2 receptor and use thereof
    Patent number: 11248023
    Abstract: The present invention relates to spexin-based agonists specific for galanin receptor type 2 and use thereof. More specifically, the present invention provides peptide-based agonists with high specificity for galanin receptor type 2 and improved stability. The peptide-based agonists are involved in the regulation of in vivo physiological functions, such as food intake, anxiety, emotion, and addiction, for which galanin receptors type 2 is responsible, to effectively suppress appetite, help recover from anxiety disorder, and reduce pleasure addiction. Therefore, the peptide-based agonists can be used to prevent or treat galanin receptor type 2-mediated diseases.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: February 15, 2022
    Assignee: Neuracle Science Co., Ltd
    Inventors: Jae Young Seong, Jong-Ik Hwang, Dong-Hoon Kim, Gi Hoon Son, Yoo-Na Lee, Seongsik Yun, Arfaxad Reyes-Alcaraz